Health Professional Radio - Podcast

Returning guest Dr. Scot Ebbinghaus with Merck Research Labs discusses data presented at the European Society for Medical Oncology (ESMO) 2019 Congress on the phase 3 PROfound trial of Merck and AstraZeneca's LYNPARZA® (olaparib) evaluating a targeted treatment in biomarker-selected metastatic castration-resistant prostate cancer patients.